TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02446769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVAPS-AE Non-invasive ventilation therapy
Description: Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
Study: NCT00049322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.~Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose.
Study: NCT01184677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insertion of the ProSeal LMA (PLMA)
Description: ProSeal LMA size 3 is inserted to the patients of Group size 3.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: insertion of the PLMA
Description: ProSeal LMA size 4 is inserted to the patients of Group size 4.
Study: NCT04538599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD13-01 cell infusion
Description: Universal CAR-T cells targeting CD7
Study: NCT03534505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketorolac group
Description: patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine group
Description: patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
Study: NCT01685411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: antithymocyte globulin
Description: Administered per institutional guidelines for recipients of umbilical cord blood transplant.
Study: NCT02712333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air Purifiers
Description: The 17 dormitory rooms and their residents were randomized into two groups: the intervention and control group. The intervention group went through a 9-day intervention with an air purifier placed in the center of the room. All rooms in this group used the same qualified air purifiers (model KJEA200e, 3M), and all participants were required to stay in their dormitory rooms with the windows/doors closed throughout intervention period. All participants and research staffs were blinded to the group assignment.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Air Purifiers
Description: The control group went through a 9-day intervention with a sham air purifier (with its filter gauze removed) placed in the center of the room. All rooms used the same air purifiers (model KJEA200e, 3M) as the intervention group, except the filter gauze was removed. During the study period all participants were required to stay in their dormitory rooms with the windows/doors closed. All participants and research staffs were blinded to the group assignment.
Study: NCT04006483

Intervention type: DRUG
Intervention: Stannous fluoride dentifrice
Description: Stannous fluoride (0.454%) dentifrice

Intervention type: DRUG
Intervention: Positive control dentifrice
Description: Positive control dentifrice containing (0.3%) triclosan.

Intervention type: DRUG
Intervention: Negative control dentifrice
Description: Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
Study: NCT01884818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulation vs. TNS thoracic pain

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manipulation vs. TNS thoracic pain
Study: NCT04172116

Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: see arm/group descriptions

Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: see arm/group descriptions
Study: NCT01283594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant (SYN115) 60 mg BID
Description: Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 60 mg BID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White-coated, modified-oval placebo tablets.
Study: NCT01284920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: oral
Study: NCT02740491

Intervention type: OTHER
Intervention: Remission Consultation
Description: At the end of adjuvant treatment (adjuvant chemotherapy and / or radiotherapy), the patient is seen by a referent oncologist and included in the study. A Remission consultation with a psychotherapist is then proposed and its purpose explained to the patient. The patient agrees or refuses take advantage of the Remission consultation; in case of refusal, the reasons are documented and further information is provided, thus giving the opportunity for the patient to benefit from further psychological counseling if desired.~If approval is given, the patient will be scheduled for the Remission consultation (duration 1 hour) . The latter includes a first phase evaluating the mental state of the patient, and then a proposal of individualized care if necessary and according to several methods, depending on the choice of the patient.
Study: NCT03035370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Boostrix™
Description: Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
Study: NCT03198247

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNE + CST
Description: The PNE and CST program will be divided in 3 individual sessions.
Study: NCT01937416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mononuclear cells
Description: Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
Study: NCT00843024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan and Naproxen Sodium
Description: Sumatriptan succinate and naproxen sodium
Study: NCT01283594

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa (L-dopa)
Description: One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa (L-dopa)
Description: One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa (L-dopa)
Description: One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa (L-dopa)
Description: One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa (L-dopa)
Description: One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
Study: NCT00843024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan and Naproxen Sodium
Description: Sumatriptan succinate and naproxen sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan and Naproxen Sodium
Description: Sumatriptan succinate and naproxen sodium
Study: NCT01283594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant (SYN115) 120 mg BID
Description: Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 120 mg BID.
Study: NCT00843024

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match
Study: NCT01283594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant (SYN115) 180 mg BID
Description: Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 180 mg BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant (SYN115) 240 mg BID
Description: Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 240 mg BID.
Study: NCT02397408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon C 11 Choline
Description: Given intravenously (IV) prior to imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Choline
Description: Given intravenously (IV) prior to imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)
Description: Undergo whole-body PET/MR imaging
Study: NCT02277145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: clinical grade umbilical cord mesenchymal stem cells
Description: 10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions
Study: NCT01741597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI
Study: NCT02151903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DI-Leu16-IL2
Description: DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
Study: NCT02195453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangzhengxiaoji Capsule
Description: Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.~Yangzhengxiaoji Capsule four granules t.i.d po.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.~Placebo Capsule four granules t.i.d po.
Study: NCT04029311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nuance Pro
Description: Study compares Nuance Pro plus Automatic Positive Airway Pressure (autoPAP) vs TAP PAP plus autoPAP
Study: NCT01741597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04029311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoPAP
Description: autoPAP
Study: NCT04257409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical intervention by exercise
Description: 12 week lasting exercise intervention
Study: NCT01741597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor-homing peptide iRGD
Description: Undergo tumor-homing peptide iRGD DCE-MRI
Study: NCT04029311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoPAP
Description: autoPAP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAP PAP
Description: TAP PAP
Study: NCT04119921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prescription topical ketorolac in group 1
Description: topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prescription artificial tear in group 2
Description: artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prescription topical ketorolac in group 2
Description: artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prescription artificial tear in group1
Description: topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
Study: NCT03265769

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radial access site
Description: radial route
Study: NCT04142892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onapristone
Description: 50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)
Study: NCT01080664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS703569
Description: Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS703569
Description: Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT03265769

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: femoral access site
Description: femoral route
Study: NCT01763983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: CBT will be delivered individually, 1 hour per week, for 12 consecutive weeks. CBT for stress in MS is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaving. Cognitive strategies include the use of dysfunctional thought records for recording and challenging negative automatic thoughts and the use of behavioural strategies to increase involvement and commitment to personal goals.~Group therapy following a similar protocol (2 hrs/week) will be offered to those in the waitlist condition after completing the study.
Study: NCT04491903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REBOA
Description: Endovascular balloon occlusion of the aorta
Study: NCT03136653

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0250 plus BOR+DEX
Description: 6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.~Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT03397771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litoxetine
Description: oral study medication provided in a dose titration manner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo medication provided in a dose titration manner
Study: NCT01340326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose of valsartan
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: OTHER
Intervention: usual dose of valsartan
Description: comparison of different dosages of drug
Study: NCT01763983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.
Study: NCT02336048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.
Study: NCT03778398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurologic music therapy
Description: Customized piano training
Study: NCT02552095

Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon PKR
Study: NCT05912491

Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal ultrasonography
Description: Transperineal ultrasound (TPU) with a Voluson E6 (GE Medical systems, Milwaukee, WI, USA). The probe was oriented to coaxially visualise the pubic symphysis on one side and the anus and rectum on the other side of the 2D image. Next, 3D/4D ultrasound was performed to obtain an image in the coronal plane at the level of the arms of the levator ani muscle, showing the pubic symphysis and the anus. All measurements were performed in three states: during pelvic muscle relaxation, during Valsalva manoeuvre, and during perineal squeezing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal ultrasonography
Description: Transperineal ultrasound (TPU) with a Voluson E6 (GE Medical systems, Milwaukee, WI, USA). The probe was oriented to coaxially visualise the pubic symphysis on one side and the anus and rectum on the other side of the 2D image. Next, 3D/4D ultrasound was performed to obtain an image in the coronal plane at the level of the arms of the levator ani muscle, showing the pubic symphysis and the anus. All measurements were performed in three states: during pelvic muscle relaxation, during Valsalva manoeuvre, and during perineal squeezing.
Study: NCT02202967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains lactose granules
Study: NCT02015949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily placebo tablet for two weeks
Study: NCT04257409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical intervention by exercise
Description: 12 week lasting exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical intervention by exercise
Description: 12 week lasting exercise intervention
Study: NCT02923531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: X4P-001 will be administered as per the dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered as per the dose and schedule specified in the arm.
Study: NCT03287323

Intervention type: OTHER
Group type: OTHER
Intervention: Proactive Palliative Care
Description: In the intervention part of the study, enrolled patients will be offered a set of different palliative care interventions, including symptom management, advance care planning, palliative physiotherapy, social and spiritual support, communication with patients and caregivers, in addition to standard intensive care.
Study: NCT03123913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.
Study: NCT05563740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial
Description: Daily telephone calls with two sessions of Brief Interventions for alcohol
Study: NCT02990754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity education
Description: Instruction in suitable physical activity options and education about physical activity with CHD.
Study: NCT03368768

Intervention type: OTHER
Intervention: Obtain inform consent via questionnaire of Monkey Survey
Description: This is an internet-based questionnaire study. Therefore, anyone in Thailand can access and answer the questionnaire.
Study: NCT02229812

Intervention type: DRUG
Intervention: alteplase
Study: NCT00228384

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GORE VIABAHN Endoprosthesis
Description: Implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Nitinol Stent
Description: Implantation
Study: NCT01168544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: loading dose Vitamin D and 50.000 IU vit D3/month
Description: loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: loading dose and 25.000 IU vit D3/month
Description: loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 800 IU /day
Description: 800 IU vit D3/day